Leerink Partnrs Issues Positive Outlook for DexCom Earnings

DexCom, Inc. (NASDAQ:DXCM) – Leerink Partnrs boosted their Q4 2024 earnings estimates for shares of DexCom in a report released on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $0.49 for the quarter, up from their prior estimate of $0.48. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s FY2026 earnings at $2.43 EPS, FY2027 earnings at $2.72 EPS and FY2028 earnings at $3.06 EPS.

Other research analysts have also issued reports about the company. Piper Sandler reissued an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Barclays dropped their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

DXCM opened at $77.83 on Tuesday. The firm has a market capitalization of $30.40 billion, a P/E ratio of 46.60, a PEG ratio of 2.23 and a beta of 1.17. The stock has a fifty day moving average of $70.76 and a 200-day moving average of $88.93. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock valued at $399,319 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Taylor Frigon Capital Management LLC boosted its holdings in DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management bought a new stake in shares of DexCom in the third quarter valued at about $683,000. National Pension Service grew its position in DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares in the last quarter. Intact Investment Management Inc. acquired a new stake in DexCom during the third quarter worth about $650,000. Finally, Waters Parkerson & CO. LLC increased its stake in DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after acquiring an additional 10,892 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.